Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Janux Therapeutics (JANX) Operating Margin (2021 - 2025)

Janux Therapeutics (JANX) has disclosed Operating Margin for 5 consecutive years, with 352.51% as the latest value for Q3 2025.

  • Quarterly Operating Margin rose 781195.0% to 352.51% in Q3 2025 from the year-ago period, while the trailing twelve-month figure was 1576.67% through Dec 2025, down 64309.0% year-over-year, with the annual reading at 1576.67% for FY2025, 64309.0% down from the prior year.
  • Operating Margin for Q3 2025 was 352.51% at Janux Therapeutics, up from 8164.46% in the prior quarter.
  • The five-year high for Operating Margin was 155.36% in Q2 2024, with the low at 8164.46% in Q3 2024.
  • Average Operating Margin over 5 years is 1338.23%, with a median of 843.51% recorded in 2021.
  • The sharpest move saw Operating Margin crashed -753622bps in 2024, then skyrocketed 781195bps in 2025.
  • Over 5 years, Operating Margin stood at 834.78% in 2021, then rose by 23bps to 642.04% in 2022, then dropped by -2bps to 655.71% in 2023, then tumbled by -1145bps to 8164.46% in 2024, then skyrocketed by 96bps to 352.51% in 2025.
  • According to Business Quant data, Operating Margin over the past three periods came in at 352.51%, 8164.46%, and 155.36% for Q3 2025, Q3 2024, and Q2 2024 respectively.